Verastem, Inc. (VSTM)Healthcare | Biotechnology | Needham, United States | NasdaqCM
5.37 USD
-0.16
(-2.893%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.24 -0.13 (-0.130%) ⇩ (July 13, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:33 a.m. EDT
Verastem presents a classic biotech dilemma where aggressive analyst targets clash with deteriorating operational reality. The company is burning significant cash, with operating cash flow deeply negative and no dividend to cushion the blow. While the stock recently rallied off lows, the underlying business shows no sign of stabilization; the market has punished the stock heavily over the last decade, and recent news of falling shares despite trial data suggests the catalysts investors hope for are elusive. The options market confirms this skepticism, with traders loading up on downside protection. Until the company demonstrates a clear path to profitability or a definitive major milestone that shifts the narrative, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.246861 |
| AutoTheta | 0.246978 |
| MSTL | 0.256336 |
| AutoARIMA | 0.284456 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.75 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | 0.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 104.522 |
| Revenue per Share | 0.617 |
| Market Cap | 471,881,440 |
| Forward P/E | -4.63 |
| Beta | 0.29 |
| Website | https://www.verastem.com |
As of July 11, 2026, 3:33 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts across multiple expirations, particularly at strikes below the current price. While there is some volume in calls, the overwhelming open interest concentration in puts suggests a fear of further downside or a hedge against clinical trial failures, rather than a bullish bet on immediate price appreciation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.114919305 |
| Address1 | 117 Kendrick Street |
| Address2 | Suite 500 |
| All Time High | 225.84 |
| All Time Low | 2.1 |
| Ask | 6.56 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 3,645,060 |
| Average Daily Volume3 Month | 2,621,922 |
| Average Volume | 2,621,922 |
| Average Volume10Days | 3,645,060 |
| Beta | 0.287 |
| Bid | 3.92 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.931 |
| City | Needham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.37 |
| Current Ratio | 3.035 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.47 |
| Day Low | 5.1 |
| Debt To Equity | 104.522 |
| Display Name | Verastem |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -169,855,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.212 |
| Enterprise To Revenue | 7.576 |
| Enterprise Value | 375,678,432 |
| Eps Current Year | -1.55667 |
| Eps Forward | -1.16 |
| Eps Trailing Twelve Months | -2.52 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4518 |
| Fifty Day Average Change | 0.9182 |
| Fifty Day Average Change Percent | 0.20625366 |
| Fifty Two Week Change Percent | 11.49193 |
| Fifty Two Week High | 11.25 |
| Fifty Two Week High Change | -5.88 |
| Fifty Two Week High Change Percent | -0.5226667 |
| Fifty Two Week Low | 3.43 |
| Fifty Two Week Low Change | 1.9399998 |
| Fifty Two Week Low Change Percent | 0.5655976 |
| Fifty Two Week Range | 3.43 - 11.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,327,674,600,000 |
| Float Shares | 70,376,240 |
| Forward Eps | -1.16 |
| Forward P E | -4.6293106 |
| Free Cashflow | -92,677,504 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.85133004 |
| Gross Profits | 42,213,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0093 |
| Held Percent Institutions | 0.98380995 |
| Implied Shares Outstanding | 87,873,639 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,685,577,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. |
| Long Name | Verastem, Inc. |
| Market | us_market |
| Market Cap | 471,881,440 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_115881768 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -193,959,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,941,223 |
| Number Of Analyst Opinions | 8 |
| Open | 5.435 |
| Operating Cashflow | -150,948,992 |
| Operating Margins | -2.40464 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 781 292 4200 |
| Post Market Change | -0.13000011 |
| Post Market Change Percent | -2.4208589 |
| Post Market Price | 5.24 |
| Post Market Time | 1,783,986,805 |
| Previous Close | 5.53 |
| Price Eps Current Year | -3.4496715 |
| Price Hint | 2 |
| Price To Book | 5.7679915 |
| Price To Sales Trailing12 Months | 9.516617 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.874 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -2.89331 |
| Regular Market Day High | 5.47 |
| Regular Market Day Low | 5.1 |
| Regular Market Day Range | 5.1 - 5.47 |
| Regular Market Open | 5.435 |
| Regular Market Previous Close | 5.53 |
| Regular Market Price | 5.37 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 2,416,426 |
| Return On Assets | -0.59405 |
| Return On Equity | -7.8615003 |
| Revenue Per Share | 0.617 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 87,873,639 |
| Shares Percent Shares Out | 0.2747 |
| Shares Short | 24,142,937 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 21,213,623 |
| Short Name | Verastem, Inc. |
| Short Percent Of Float | 0.2764 |
| Short Ratio | 8.14 |
| Source Interval | 15 |
| State | MA |
| Symbol | VSTM |
| Target High Price | 18.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 15.0 |
| Target Median Price | 15.0 |
| Total Cash | 181,678,000 |
| Total Cash Per Share | 2.067 |
| Total Debt | 85,475,000 |
| Total Revenue | 49,585,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.52 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.6661 |
| Two Hundred Day Average Change | -1.2961001 |
| Two Hundred Day Average Change Percent | -0.19443154 |
| Type Disp | Equity |
| Volume | 2,416,426 |
| Website | https://www.verastem.com |
| Zip | 2,494 |